Overview

Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB)

Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.
Phase:
Phase 4
Details
Lead Sponsor:
Urovant Sciences GmbH